Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002176 · ClinicalTrials.gov registry record · NA
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
A NA study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
NCT00002176: Completed NA study, sponsored by Bristol-Myers Squibb.
NCT00002176 is a NA study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002176, a NA study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of this therapy over CD4 cell counts.
Interventions
- DRUG Hydroxyurea
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-05 |
| Est. Completion | 2000-03 |
| Phase | NA |
What the finished NCT00002176 record still lists
NCT00002176 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which Hydroxyurea is the first listed.
NCT00002176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002176 about?
NCT00002176 is a clinical study titled "A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection". To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma. To assess the long-term safety and tolerability of this combination therapy and the magnitude and duration of the effect of this therapy over CD4 ...
What is the current status of trial NCT00002176?
This trial is currently completed. It is a NA study. The study started on 1997-05. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00002176?
The interventions under investigation include: Hydroxyurea (DRUG), Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002176?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia